Chris Jones

Chris Jones

Auto-generated profile, based on publicly available information

Chris Jones

Division of Molecular Pathology, Institute of Cancer Research, London, United Kingdom

Research Focus & Metrics

Academic Career Length

34Years (1993-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2018 in Nature
Verified
Journal Article
Open access
PDF file
DCDavid Capper
David Capper
DJDavid T. W. Jones
David T. W. Jones
MSMartin Sill
Martin Sill
VHVolker Hovestadt
Volker Hovestadt
DSDaniel Schrimpf
Daniel Schrimpf
SPStefan M. Pfister
Stefan M. Pfister
Accurate pathological diagnosis is crucial for optimal management of patients with cancer. For the approximately 100 known tumour types of the central nervous system, standardization of the diagnostic process has been shown to be particularly challenging—with substantial inter-observer variability in the histopathological diagnosis of many tumour types. Here we present a comprehensive approach for the DNA methylation-based classification of central nervous system tumours across all entities and age groups, and demonstrate its application in a routine diagnostic setting. We show that the availability of this method may have a substantial impact on diagnostic precision compared to standard methods, resulting in a change of diagnosis in up to 12% of prospective cases. For broader accessibility, we have designed a free online classifier tool, the use of which does not require any additional onsite data processing. Our results provide a blueprint for the generation of machine-learning-based tumour classifiers across other cancer entities, with the potential to fundamentally transform tumour pathology.

1 October 2017 in Cancer Cell
Verified
Journal Article
Open access
AMAlan Mackay
Alan Mackay
ABAnna Burford
Anna Burford
DCDiana Carvalho
Diana Carvalho
EIElisa Izquierdo
Elisa Izquierdo
JFJanat Fazal-Salom
Janat Fazal-Salom
CJChris Jones
Chris Jones
We collated data from 157 unpublished cases of pediatric high-grade glioma and diffuse intrinsic pontine glioma and 20 publicly available datasets in an integrated analysis of >1,000 cases. We identified co-segregating mutations in histone-mutant subgroups including loss of FBXW7 in H3.3G34R/V, TOP3A rearrangements in H3.3K27M, and BCOR mutations in H3.1K27M. Histone wild-type subgroups are refined by the presence of key oncogenic events or methylation profiles more closely resembling lower-grade tumors. Genomic aberrations increase with age, highlighting the infant population as biologically and clinically distinct. Uncommon pathway dysregulation is seen in small subsets of tumors, further defining the molecular diversity of the disease, opening up avenues for biological study and providing a basis for functionally defined future treatment stratification.

1 February 2016 in Cell
Verified
Journal Article
Closed access
DSDominik Sturm
Dominik Sturm
BOBrent A. Orr
Brent A. Orr
UTUmut H. Toprak
Umut H. Toprak
VHVolker Hovestadt
Volker Hovestadt
DJDavid T.W. Jones
David T.W. Jones
MKMarcel Kool
Marcel Kool

1 November 2013 in Cancer Cell
Verified
Journal Article
Closed access
SBSebastian Bender
Sebastian Bender
YTYujie Tang
Yujie Tang
ALAnders M. Lindroth
Anders M. Lindroth
VHVolker Hovestadt
Volker Hovestadt
DJDavid T.W. Jones
David T.W. Jones
Stefan PfisterStefan Pfister
Stefan Pfister

23 September 2015 in Acta Neuropathologica
Verified
Journal Article
Open access
PDF file
DCDavid Castel
David Castel
CPCathy PHILIPPE
Cathy PHILIPPE
RCRaphaël Calmon
Raphaël Calmon
LDLudivine Le Dret
Ludivine Le Dret
NTNathalène Truffaux
Nathalène Truffaux
MDMarie-Anne Debily
Marie-Anne Debily
Diffuse intrinsic pontine glioma (DIPG) is the most severe paediatric solid tumour, with no significant therapeutic progress made in the past 50 years. Recent studies suggest that diffuse midline glioma, H3-K27M mutant, may comprise more than one biological entity. The aim of the study was to determine the clinical and biological variables that most impact their prognosis. Ninety-one patients with classically defined DIPG underwent a systematic stereotactic biopsy and were included in this observational retrospective study. Histone H3 genes mutations were assessed by immunochemistry and direct sequencing, whilst global gene expression profiling and chromosomal imbalances were determined by microarrays. A full description of the MRI findings at diagnosis and at relapse was integrated with the molecular profiling data and clinical outcome. All DIPG but one were found to harbour either a somatic H3-K27M mutation and/or loss of H3K27 trimethylation. We also discovered a novel K27M mutation in HIST2H3C, and a lysine-to-isoleucine substitution (K27I) in H3F3A, also creating a loss of trimethylation. Patients with tumours harbouring a K27M mutation in H3.3 (H3F3A) did not respond clinically to radiotherapy as well, relapsed significantly earlier and exhibited more metastatic recurrences than those in H3.1 (HIST1H3B/C). H3.3-K27M-mutated DIPG have a proneural/oligodendroglial phenotype and a pro-metastatic gene expression signature with PDGFRA activation, while H3.1-K27M-mutated tumours exhibit a mesenchymal/astrocytic phenotype and a pro-angiogenic/hypoxic signature supported by expression profiling and radiological findings. H3K27 alterations appear as the founding event in DIPG and the mutations in the two main histone H3 variants drive two distinct oncogenic programmes with potential specific therapeutic targets.

6 April 2014 in Nature Genetics
Verified
Journal Article
Open access
PDF file
PBPawel Buczkowicz
Pawel Buczkowicz
CHChristine Hoeman
Christine Hoeman
PRPatricia Rakopoulos
Patricia Rakopoulos
SPSanja Pajovic
Sanja Pajovic
LLLouis Letourneau
Louis Letourneau
CHCynthia Hawkins
Cynthia Hawkins
Cynthia Hawkins, Oren Becher and colleagues report the identification of recurrent mutations in ACVR1 in 20% of diffuse intrinsic pontine gliomas. Diffuse intrinsic pontine glioma (DIPG) is a fatal brain cancer that arises in the brainstem of children, with no effective treatment and near 100% fatality. The failure of most therapies can be attributed to the delicate location of these tumors and to the selection of therapies on the basis of assumptions that DIPGs are molecularly similar to adult disease. Recent studies have unraveled the unique genetic makeup of this brain cancer, with nearly 80% found to harbor a p.Lys27Met histone H3.3 or p.Lys27Met histone H3.1 alteration. However, DIPGs are still thought of as one disease, with limited understanding of the genetic drivers of these tumors. To understand what drives DIPGs, we integrated whole-genome sequencing with methylation, expression and copy number profiling, discovering that DIPGs comprise three molecularly distinct subgroups (H3-K27M, silent and MYCN) and uncovering a new recurrent activating mutation affecting the activin receptor gene ACVR1 in 20% of DIPGs. Mutations in ACVR1 were constitutively activating, leading to SMAD phosphorylation and increased expression of the downstream activin signaling targets ID1 and ID2. Our results highlight distinct molecular subgroups and novel therapeutic targets for this incurable pediatric cancer.